Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study

Minh Patrick Lê, Marc Antoine Valantin, Lambert Assoumou, Cathia Soulié, Soizic Le Mestre, Laurence Weiss, Yazdan Yazdanpanah, Jean Michel Molina, Olivier Bouchaud, Francois Raffi, et al.

To cite this version:

HAL Id: hal-02442744
https://hal.archives-ouvertes.fr/hal-02442744
Submitted on 16 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study

Minh Patrick Lê,^1,2,* Marc-Antoine Valantin,^3,4 Lambert Assoumou,^4 Cathia Soulie,^5 Soizic Le Mestre,^6 Laurence Weiss,^7 Yazdan Yazdanpanah,^1,8 Jean-Michel Molina,^9 Olivier Bouchaud,^10 François Raffi,^11 Jacques Reynes,^12,13 Vincent Calvez,^5 Anne-Geneviève Marcelin,^5 Dominique Costagliola,^4 Christine Katlama,^3,4 and Gilles Peytavin,^1,2 ANRS-163 ETRAL study group†

†IAME, UMR 1137, Sorbonne Paris Cité and INSERM, Université Paris Diderot, Paris, France; ‡Laboratoire de Pharmacologie-Toxicologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France; §Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France; †INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique (iPESL UMR 1136), Sorbonne Université, UPMC Univ Paris 06, Paris, France; ‡Laboratoire de Virologie, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique (iPESL), AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France; §France Recherche Nord & Sud SIDA-HIV Hépatites (ANRS), Paris, France; †Service d’Immunologie Clinique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; ‡Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France; §Service de Maladies Infectieuses et Tropicales, INSERM U941, AP-HP, Hôpital Saint Louis, Université Denis Diderot Paris VII, Paris, France; †Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Avicenne, Bobigny, France; ‡Département of Infectious Diseases, Hotel-Dieu Hospital – INSERM CIC 1413, Nantes University Hospital, Nantes, France; †Service de Maladies Infectieuses et Tropicales, CHU Montpellier, Montpellier, France; ‡INSERM U1175, IRD UMI 233, University of Montpellier, Montpellier, France

STUDY OBJECTIVE The ANRS163-ETRAL study showed that etravirine 200 mg/raltegravir 400 mg twice-daily dual therapy was highly effective in the treatment of human immunodeficiency virus (HIV)-infected patients older than 45 years, with virologic and therapeutic success rates at week 48 of 99.4% and 94.5%, respectively. The objective of this study was to determine whether a clinically
significant pharmacokinetic interaction between etravirine and raltegravir exists by assessing steady-state total and unbound etravirine, raltegravir, and inactive raltegravir-glucuronide concentrations 12 hours after last intake (C_{12h}) in blood plasma (BP) and seminal plasma (SP).

**DESIGN** Pharmacokinetic analysis of data from the ANRS163-ETRAL study.

**PATIENTS** One hundred forty-six HIV-1–infected patients (of the 165 patients included in the ANRS-163 ETRAL study) who were receiving etravirine 200 mg and raltegravir 400 mg twice daily.

**MEASUREMENTS AND MAIN RESULTS** Blood was collected from all 146 patients at weeks 2–4, 12, 24, and 48, and semen was collected from 21 patients at week 48. The extent of BP and SP protein binding was determined by using ultrafiltration assay. Total and unbound etravirine, raltegravir, and raltegravir-glucuronide C_{12h} were determined by ultra high performance liquid chromatography coupled with tandem mass spectrometry and interpreted by using the in vitro calculated protein-bound 95% inhibitory concentration (PBIC_{95}) for wild-type (WT) HIV: etravirine (116 ng/ml) and raltegravir (15 ng/ml). Median (interquartile range [IQR]) total BP etravirine C_{12h} (536 ng/ml [376–719]) and raltegravir (278 ng/ml [97–690]) were adequate in 99% and 96% of patients, respectively. Median (IQR) SP:BP C_{12h} ratio and BP unbound fraction were etravirine 0.3 (0.2–0.5) and <1%, respectively, raltegravir 1.8 (1.3–3.3) and 12%, respectively, and raltegravir-glucuronide 12.0 (6.5–17.7) and >99%, respectively. The BP raltegravir metabolic ratio (raltegravir glucuronide:raltegravir ratio) was 1.7, suggesting only weak induction of raltegravir glucuronidation by etravirine. Only three patients had etravirine and raltegravir C_{12h} < PBIC_{95} simultaneously.

**CONCLUSION** No clinically significant pharmacokinetic interaction between etravirine and raltegravir was detected. Total etravirine and raltegravir BP concentrations were adequate in most patients, favoring virologic efficacy and confirming good treatment adherence (>95%), despite twice-daily administration. The long half-life of etravirine and higher unbound fraction SP of raltegravir (57%) ensured adequate concentrations of dual therapy in genital compartments. Our results indicate that etravirine and raltegravir have good, complementary pharmacokinetic profiles, suggesting that they could be used in a dual-treatment strategy.

**KEY WORDS** dual therapy, antiretroviral, etravirine, raltegravir, pharmacokinetics, seminal fluid, interaction.


**Introduction**

There is growing clinical interest in the evaluation of new antiretroviral strategies sparing nucleoside analogs (nucleoside/nucleotide reverse transcriptase inhibitors [NRTIs]) and protease inhibitors (PIs), particularly in aging populations with a long cumulative exposure to antiretroviral drugs. NRTIs and PIs have been associated with cumulative long-term toxicity, with bone and renal disorders reported in patients taking tenofovir and an increase in cardiovascular risk for patients taking PIs. The aging of patients with human immunodeficiency virus (HIV) infection is now a major concern, given the increase in polypharmacy prescriptions due to the higher rates of comorbidities such as bone demineralization, cardiovascular and cerebrovascular disease, diabetes mellitus, and renal dysfunction. The increase in polypharmacy prescription rates raises questions about drug–drug interactions (DDIs), particularly for antihypertensive agents, anticoagulants, statins, and antiepileptic drugs that are cytochrome P450 (CYP) or P-glycoprotein (P-gp) substrates. Strategies for long-term virologic suppressive therapies with less DDI potential are required for patients with comorbid conditions. These alternative strategies must maintain HIV suppression, in all compartments, while minimizing the occurrence of long-term clinical and metabolic complications.

The results of a pilot study evaluating a dual-treatment strategy based on the twice-daily administration of etravirine/raltegravir suggested that such NRTI/PI-sparing strategies were a potential option for maintaining virologic suppression at week 48 (W48) while minimizing DDIs. Etravirine, a non-nucleoside analog (nonnucleoside reverse transcriptase inhibitor [NNRTI]), and raltegravir, an integrase inhibitor, have good efficacy profiles. Etravirine remains active against viruses harboring single K103N mutations (signature of first-generation
NNRTIs), and raltegravir trended to be superior to efavirenz after 5 years of treatment in the STARTMRK study. Both compounds have good reported safety profiles, reducing the risk of long-term toxicity. Contrary interpretations of a DDI between etravirine and raltegravir are reported throughout the literature, although limited data are available for this dual regimen.

The ANRS-163 ETRAL trial (ClinicalTrials.gov identifier NCT02212379) was a 96-week, international, multicenter, open phase II trial. Its principal objective was to evaluate, at W48, the capacity of the etravirine/raltegravir combination to maintain virologic success in HIV-1–infected patients of at least 45 years of age with suppressed viremia (plasma HIV RNA < 50 copies/ml) switching from a boosted PI-containing regimen. This strategy was found to be highly effective and safe in these patients, with virologic and therapeutic success rates of 99.4% and 94.5%, respectively, at W48.

Etravirine is mainly metabolized by CYP3A4, CYP2C9, and CYP2C19 and is an inducer of CYP3A4 and inhibitor of CYP2C9 and CYP2C19, whereas raltegravir is mainly metabolized by uridine diphosphoglucuronosyltransferase (UGT) 1A1, without the involvement of CYP, and does not inhibit P-gp–mediated transport. However, considerable inter- and intraindividual variability has been observed in the pharmacokinetics of raltegravir.

In this pharmacokinetic substudy, the objective was to assess steady-state total and unbound concentrations 12 hours after last intake (C12h) of etravirine, raltegravir, and raltegravir glucuronide, in both blood and seminal plasma from HIV-1–infected patients receiving etravirine 200 mg twice daily and raltegravir 400 mg twice daily to determine whether a clinically significant pharmacokinetic interaction between etravirine and raltegravir exists and to support the efficacy and safety results of the ANRS-163 ETRAL study.

Methods

In this pharmacokinetic analysis, the eligibility criteria were those of the ANRS-163 ETRAL trial: HIV-1 infection; age > 45 years; naive for integrase inhibitors and etravirine; > 6 months of stable antiretroviral therapy including a boosted PI, whatever the number of combined drugs; plasma HIV RNA ≤ 50 copies/ml during the last 24 months, and no DDIs between concomitant medications and etravirine or raltegravir, based on their respective product information. Written informed consent for this pharmacokinetic substudy, including consent for collection of semen samples, was obtained with participation to the main study. The study protocol was reviewed and approved by the local ethics committees and was conducted in accordance with the Declaration of Helsinki.

Blood samples were collected at W2–4, W12, W24, and W48 12 ± 2 hours after the last intake. Semen samples were collected at W48 within the hour after the blood sampling. Blood and seminal plasma samples were immediately centrifuged, and the respective samples were stored at −80°C. All patients were considered to be at steady state by W2 according to the respective elimination half-lives of etravirine (30–40 hrs) and raltegravir (9 hrs). Binding to blood and seminal plasma proteins was assessed for all samples in an ultrafiltration assay (Centrifree; Millipore, Molsheim, France) of 400-μl samples (2000 g for 30 min at 25°C). Blood and seminal plasma concentrations of etravirine, raltegravir, and raltegravir glucuronide were determined by ultra high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-M5/MS; Waters Acquity UPLC-TQD, Milford, MA). The limit of quantification was < 5 ng/ml for all assays, and interpretation was based on the corresponding in vitro protein-adjusted 95% inhibitory
concentration (PBIC\textsubscript{95}) for wild-type (WT) HIV-1: 116 ng/ml\textsuperscript{16} for etravirine and 15 ng/ml for raltegravir.\textsuperscript{17} Etravirine and raltegravir C\textsubscript{12h} were considered to be adequate if above the respective PBIC\textsubscript{95}. Metabolic ratio was determined as the raltegravir glucuronide:raltegravir ratio.

Statistical Analysis

Results are presented as median (interquartile range [IQR]) values. Mann-Whitney and Kruskal-Wallis tests were used for statistical comparisons between the four sample collection visits. No correction for multiple comparisons was performed, and a p value < 0.05 was considered to indicate a statistically significant difference.

Results

We included 146 of the 165 patients from the ANRS-163 ETARAL study in this pharmacokinetic analysis. Baseline characteristics of the 146 patients are presented in Table 1. Median age was 52 (IQR 48–58) years, 71% were male, 75% were Caucasian and 15% were from sub-Saharan Africa, and median duration of viremia suppression was 6.9 (IQR 3.4–9.3) years.

For the 504 blood samples collected from the 146 patients during 48 weeks (four visits), the median total blood plasma C\textsubscript{12h} values of etravirine and raltegravir were 536 ng/ml (IQR 376–719) and 278 ng/ml (IQR 97–690), respectively. Total blood plasma C\textsubscript{12h} values are presented for the four visits in Table 2. The C\textsubscript{12h} of etravirine, raltegravir, and raltegravir glucuronide did not significantly differ between visits. Overall, blood plasma concentrations of etravirine and raltegravir were above the corresponding PBIC\textsubscript{95} in 99% for etravirine and 96% for raltegravir, with only three patients with both etravirine and raltegravir blood plasma C\textsubscript{12h} < PBIC\textsubscript{95}. The median fractions of the drugs remaining unbound in blood plasma were < 1% for etravirine, 12% for raltegravir (IQR 10–15%) and > 99% for raltegravir glucuronide (IQR 91–100%), with no significant changes observed during the study period. Low median interpatient and interoccasion variabilities were recorded for total etravirine blood plasma C\textsubscript{12h} of 45% and 24%, respectively, in contrast with total raltegravir blood plasma C\textsubscript{12h} of 166% and 91%, respectively. Total blood plasma metabolic ratio (raltegravir glucuronide: raltegravir C\textsubscript{12h}) was 1.7 (1.1–2.8) and remained stable over time (Table 2). Finally, 21 semen samples were collected from 21 patients. Median seminal:blood plasma C\textsubscript{12h} ratios were 0.3 (0.2–0.5) for total etravirine, 1.8 (1.3–3.3) for total raltegravir, 12.0 (6.5–17.7) for unbound raltegravir, 5.7 (2.0–11.6) for total raltegravir glucuronide, and 2.4 (0.8–4.1) for unbound raltegravir glucuronide (geometric means [95% confidence intervals] data are presented in Figure 1). The seminal:blood plasma ratio of unbound etravirine could not be determined because all unbound concentrations of etravirine were below the limit of quantification.

Discussion

To our knowledge, this is the first study to determine whether an interaction exists between etravirine and raltegravir in a dual maintenance antiretroviral regimen without any other interfering antiretroviral agent. In this study of HIV-1-infected patients (>45 years of age) with suppressed viremia switching from a boosted PI-containing regimen to dual therapy, etravirine and raltegravir blood plasma C\textsubscript{12h} were consistent with findings published separately and the information provided with the products. As expected, no evident DDI between etravirine and raltegravir was reported with no significant difference in etravirine and raltegravir C\textsubscript{12h} between the four sample collection visits (Table 2). Moreover, these results are consistent with published data from healthy subjects.\textsuperscript{9} Most patients had adequate blood plasma C\textsubscript{12h} for etravirine (<1% of patients with C\textsubscript{12h} < PBIC\textsubscript{95}) and raltegravir.

Table 1. Baseline Characteristics of the Study Patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Data (n=146)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>52 (48–58)</td>
</tr>
<tr>
<td>Male sex</td>
<td>103 (71%)</td>
</tr>
<tr>
<td>Race-ethnicity</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>109 (75%)</td>
</tr>
<tr>
<td>Sub-Saharan African</td>
<td>22 (15%)</td>
</tr>
<tr>
<td>Other</td>
<td>15 (10%)</td>
</tr>
<tr>
<td>HCV coinfection</td>
<td>14 (10%)</td>
</tr>
<tr>
<td>Duration of suppressed</td>
<td>6.9 (3.4–9.3)</td>
</tr>
<tr>
<td>plasma HIV-RNA (&lt; 50 copies/ml; yrs)</td>
<td></td>
</tr>
<tr>
<td>Duration of last ART (yrs)</td>
<td>4.8 (2.7–7.4)</td>
</tr>
<tr>
<td>Last ART once-daily dosing</td>
<td>107 (73%)</td>
</tr>
<tr>
<td>Last ART regimen</td>
<td></td>
</tr>
<tr>
<td>2 NRTIs + PI/r</td>
<td>95 (65%)</td>
</tr>
<tr>
<td>NNRTI + PI/r</td>
<td>10 (7%)</td>
</tr>
<tr>
<td>PI/r</td>
<td>31 (21%)</td>
</tr>
<tr>
<td>Other</td>
<td>10 (7%)</td>
</tr>
</tbody>
</table>

Data are no. (%) of patients or median (interquartile range) values. ART = antiretroviral treatment; HCV = hepatitis C virus; HIV = human immunodeficiency virus; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside/nucleotide reverse transcriptase inhibitor; PI/r = ritonavir-boosted protease inhibitor.
Table 2. Total and Unbound Blood and Seminal Plasma Trough Concentrations of Etravirine, Raltegravir, and Raltegravir Glucuronide, and Total and Unbound Metabolic Ratios

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study Visit</th>
<th>Weeks 2–4</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Week 48</th>
<th>p Value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of blood samples (one sample/patient)</td>
<td>125</td>
<td>138</td>
<td>138</td>
<td>103</td>
<td>0.0691</td>
<td></td>
</tr>
<tr>
<td>Total etravirine C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>507 (364–733)</td>
<td>538 (373–710)</td>
<td>532 (373–693)</td>
<td>586 (434–819)</td>
<td>0.0691</td>
<td></td>
</tr>
<tr>
<td>Unbound etravirine C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>0.8991</td>
<td></td>
</tr>
<tr>
<td>Total raltegravir C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>278 (97–599)</td>
<td>352 (97–741)</td>
<td>223 (83–834)</td>
<td>267 (111–737)</td>
<td>0.8991</td>
<td></td>
</tr>
<tr>
<td>Unbound raltegravir C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>41 (18–82)</td>
<td>45 (13–93)</td>
<td>30 (11–109)</td>
<td>30 (13–83)</td>
<td>0.4342</td>
<td></td>
</tr>
<tr>
<td>Total raltegravir glucuronide C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>544 (246–1297)</td>
<td>541 (227–1355)</td>
<td>521 (196–1338)</td>
<td>535 (240–1018)</td>
<td>0.7991</td>
<td></td>
</tr>
<tr>
<td>Unbound raltegravir glucuronide C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>589 (277–1446)</td>
<td>614 (230–1612)</td>
<td>666 (253–1390)</td>
<td>519 (242–1077)</td>
<td>0.7183</td>
<td></td>
</tr>
<tr>
<td>Total raltegravir metabolic ratio</td>
<td>2.0 (1.1–3.1)</td>
<td>1.6 (1.1–2.8)</td>
<td>1.6 (1.0–3.0)</td>
<td>1.6 (1.0–2.3)</td>
<td>0.3311</td>
<td></td>
</tr>
<tr>
<td>Unbound raltegravir metabolic ratio</td>
<td>15.9 (9.6–26.2)</td>
<td>15.0 (10.4–23.6)</td>
<td>16.9 (10.9–26.7)</td>
<td>16.7 (9.9–25.9)</td>
<td>0.7904</td>
<td></td>
</tr>
<tr>
<td>No. of seminal samples (one sample/patient)</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Total etravirine C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>122 (98–229)</td>
<td>122 (98–229)</td>
<td>122 (98–229)</td>
<td>122 (98–229)</td>
<td>0.8991</td>
<td></td>
</tr>
<tr>
<td>Unbound etravirine C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td>&lt; 5 (NA)</td>
<td></td>
</tr>
<tr>
<td>Total raltegravir C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>560 (348–798)</td>
<td>397 (217–512)</td>
<td>2931 (1070–5908)</td>
<td>1359 (429–2411)</td>
<td>0.8991</td>
<td></td>
</tr>
<tr>
<td>Unbound raltegravir C&lt;sub&gt;12h&lt;/sub&gt; (ng/ml)</td>
<td>397 (217–512)</td>
<td>2931 (1070–5908)</td>
<td>1359 (429–2411)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are median (interquartile range) values.
C<sub>12</sub> = 12 hours after last intake; NA = not applicable.
<sup>a</sup>Statistical analysis was based on nonparametric Kruskal-Wallis tests, with significance defined as p<0.05.

Figure 1. Seminal/blood plasma ratios for total and unbound etravirine, raltegravir, and raltegravir glucuronide at week 48 (n = 21). Symbols and whiskers show geometric means and 95% confidence intervals. Ratios < 1 are interpreted as moderate seminal penetration, and ratios > 1 as good seminal penetration.
(< 5% of patients with C12h < PBIC95), consistent with the observed high virologic efficacy at W48 and confirming excellent treatment adherence (> 95%), despite twice-daily dosing (only three patients had both etravirine and raltegravir C12h < PBIC95), as most patients (73%) were taking a once-daily antiretroviral drug regimen before switching.

Surprisingly, despite the lack of an expected DDI with etravirine, the total metabolic ratio of raltegravir glucuronide/raltegravir appeared to be lower than that reported in the Belkhir et al.18 study, regardless of the UGT1A1 polymorphism. To the contrary, our total metabolic ratio results were consistent with previous results in healthy volunteers.9, 19 Nevertheless, the decrease in metabolic ratio might also be explained by higher elimination of the raltegravir glucuronide due to an induction of the expression of genes coding for efflux transporters.20

One key concern related to the less-drug antiretroviral drug strategies is the penetration of the drugs into deep compartments. Moderate penetration of etravirine into the seminal compartment was observed in our patients (Figure 1), consistent with previous results (including patients receiving a ritonavir-boosted PI-containing regimen).21, 22 This moderate penetration is probably due to its high plasma protein binding, compensated by its long elimination half-life and low variability.10 In contrast, raltegravir penetration into the seminal compartment was reported to be lower, but also with a lower variability, than in previous studies, which might be mechanistically explained by the induction of the efflux of raltegravir from the semen.22–27

Raltegravir is transported by P-gp/ABCB1 but also by BCRP/ABCG2,27 which are both highly expressed in epididymis28 and induced by etravirine.20, 29 Etravirine, after a single dose, was also reported to be a potent inhibitor of BCRP/ABCG2 and not an inhibitor of P-gp/ABCB1.20, 29 Our results at steady state suggest that the induction of both P-gp/ABCB1 and BCRP/ABCG2 might be of greater impact than the sole inhibition of BCRP/ABCG2. Despite the probable interaction through the efflux transporters, the seminal concentration of raltegravir remained above the PBIC95, suggesting sufficient penetration in this compartment. The mechanistic hypothesis of the DDI remains difficult to assess probably due to the erratic pharmacokinetic profile of raltegravir and the paucity of data concerning the seminal penetration of raltegravir (particularly raltegravir glucuronide and the unbound fraction of both raltegravir and its glucuronide metabolite) without coadministration of compounds such as ritonavir-boosted PIs or NNRTIs that might also impact efflux transporters. Finally, the inducer potential of etravirine on efflux transporters raises the question of the DDI with concomitant medications, which might be underestimated, and their clinical relevance depending on their respective therapeutic indexes.

The main limitations of our study would be that the study was not designed for a bioequivalence assessment with sampling allowing determination of both maximum concentration and area under the concentration-time curve from time 0 to 24 hours. Also, cervicovaginal secretions were not obtained since the study was a multicenter study, and the sampling method was critical.

Conclusion

In this ANRS-163 ETRLA pharmacokinetic sub-study, no clinically significant pharmacokinetic interaction between etravirine and raltegravir was detected. Total and unbound blood plasma concentrations of etravirine, raltegravir, and raltegravir glucuronide remained stable over the study period. Overall, the etravirine/raltegravir dual regimen seems to provide adequate blood plasma exposure and seminal penetration in accordance with the high virologic and therapeutic success rates of 99.4% and 94.5%, respectively. Given the excellent results for both adherence and virologic data obtained for the blood and seminal compartments, our results indicate that etravirine and raltegravir have good, complementary pharmacokinetic profiles, suggesting that they could be used in a dual-treatment strategy.

Acknowledgments

The authors thank all the participating patients and the study nurses at the clinical sites. Study investigators and participating centers are as follows: Claudine Duvi- vier (AP-HP, Hôpital Necker, Paris), Cécile Goujard (AP-HP, Hôpital Bicêtre, Kremlin-Bicêtre), Vincent Jeantils (AP-HP, Hôpital Jean Verdier, Bondy), Olivier Bouchaud (AP-HP, Hôpital Avicenne, Bobigny), Laurence Weiss (AP-HP, AP-HP, Hôpital Européen Georges Pompidou, Paris), Dominique Salmon (AP-HP, Hôpital Cochin, Paris), Marc-Antoine Valantin (AP-HP, Hôpi-tal Pitié Salpêtrière, Paris), Anne Simon (AP-HP, Hôpi-tal Pitié Salpêtrière, Paris), Jean Michel Molina, Nathalie Colin de Verdière (AP-HP, Hôpital Saint Louis, Paris), Philippe Morlat (Saint André, Bordeaux), Isabelle Poizot-Martin (AP-HM, Hôpital Sainte-Marguerite, Marseille), Yazdan Yazdapanah (AP-HP, Hôpital
References


